Monday, May 28, 2018

(Reuters) - U.S. regulators on Thursday approved BioMarin Pharmaceutical Inc's Palynziq for adults with phenylketonuria, a rare metabolic disorder, sending shares of the biotechnology company up 3 percent after hours.


from Reuters: Health News https://ift.tt/2s4ng4Y

Related Posts:

  • LATEST HEALTH NEWSSince patient's own cells are taken in this process, the risk of immune rejection is completely avoided from Health https://ift.tt/2SIKk4L … Read More
  • LATEST HEALTH NEWSBeing out of shape increased someone's risk of dying early as much as smoking did, study found from Health https://ift.tt/2PaqTUs … Read More
  • LATEST HEALTH NEWSSurgery on legs, family history, smoking and hormone therapy are also risk factors for varicose veins from Health https://ift.tt/2Dl0QUi … Read More
  • LATEST HEALTH NEWSDrug-resistant bacteria killed more than 33,000 people in Europe in 2015, according to new research published separately this week from Health https://ift.tt/2zACmBT … Read More
  • LATEST HEALTH NEWSPatients reported more improvement in their insomnia symptoms after 4, 8 and 24 weeks from Health https://ift.tt/2JBz9GY … Read More

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner